A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings

NCT05527041 | Enrolling By Invitation FDA Device

• 1 other identifier: W81XWH21C0103
• Study Type: observational
• Target: 1,600
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to develop a highly portable, ruggedized diagnostic tool for concussion, EyeBOX Lens (EBLens), that can be utilized in deployed field and far-forward settings. The EBLens will be based on a concussion diagnostic algorithm from the FDA cleared EyeBOX device, developed by Oculogica, and eye-tracking data collected from a wearable set of eye-tracking glasses, developed by Adhawk Microsystems. Once the EBLens is prototyped, an algorithm for diagnosing concussion will be developed that is specifically appropriate for the EBLens via a case-control clinical study comparing 100 concussed to 100 non-concussed subjects (Phase I). Participants, age 18-35 years, will be recruited from the KACH research team and affiliated providers and clinical sites. Concussed individuals will be assessed within 72 hours of concussion. Demographics, basic medical history, symptom severity, a visio-vestibular exam and the EBLens scan will be collected on both injured cases and uninjured controls at a single time point. The algorithm and the EBLens will be validated in a subsequent, prospective cohort validation study (Phase II) designed for FDA submission. The correlation of the EBLens output with resolution of symptoms will also be observed in longitudinal follow-up of concussed participants in the validation study. The participant population for this study will be cadets recruited from the USMA and young athletes recruited from affiliated sites during baseline concussion testing. Participants will be assessed at baseline at the start of their academic year or sports season. Those participants who experience a concussive injury will be assessed again at three time points; 1) within 72 hours of injury, 2) weekly until and at the time of initiation of a graded return to activity protocol, and 3) upon clearance for unrestricted RTP/RTD.

Conditions

Concussion, Brain; Mild Traumatic Brain Injury

Keywords

Traumatic Brain Injury; Eye-tracking; Far-forward Settings; Return-to-Activity; Diagnostic

Outcome Measures

Primary Outcomes (1)

• Diagnostic accuracy of acute clinical diagnosis of concussion using EBLens form factor and algorithm

  The EBLens will have at least 70% sensitivity and specificity for diagnosis of acute concussion

  Within 72 hours of injury

Secondary Outcomes (1)

• Diagnostic accuracy of recovery determination for return to activity and duty (RTA / RTD) using EBLens form factor and algorithm

  Through study completion, up to one year

Study Arms (2)

Concussed

Subjects age 17-34 years within 72 hours of injury.

Device: EyeBOX Lens (EBLens)

Non-concussed

In Phase I, uninjured, matched controls. In Phase II, subjects completing baseline concussion testing as part of the standard of care or athletics pre-season.

Device: EyeBOX Lens (EBLens)

Interventions

EyeBOX Lens (EBLens) DEVICE

The investigational device, EBLens, consists of eye-tracking scanners and sensors, developed by AdHawk Microsystems, embedded into a rugged pair of eye-glasses. The subject will wear the EBLens form factor while seated about 40 cm from a small handheld computer screen. The subject will be instructed to watch a video on the screen, while trying not to move their head. The operator will then initiate the EBLens test sequence. During this test a video will be displayed on only a portion of the screen (aperture about 1/9 the size of the screen) for 90 seconds. The video aperture will begin in the upper left corner, and, after 10 seconds, moves in a clockwise direction around the screen for 2 cycles, each taking 40 seconds. During the scan, the following data are collected at a frame rate from 100 to 500 Hz: * Gaze coordinates * Pupil sizes * Accelerometer data * Gyroscopic data * Rotation data * Blink data

Concussed; Non-concussed

Eligibility Criteria

• Age: 17 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Participants will be young athletes or cadets between the ages of 18-35. Cadets at the USMA who are 17 and are emancipated will also be included. To be included in the algorithm development study, subjects must either be uninjured (to fall into the uninjured cohort) or have experienced a concussive event (to fall into the injured cohort). In the validation study, subjects must be participants who have completed baseline testing and have consented to participate.

You may qualify if:

• Provide documented informed consent.
• Have presented, at any time post injury, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
• Be a current cadet/enrolled student age 17-34.
• Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.

You may not qualify if:

• Have penetrating trauma or known skull fracture or intracranial injury.
• Have had a conventional head CT or MRI demonstrating evidence of structural brain injury (subdural, epidural or intraparenchymal hemorrhage, edema/mass effect per attending radiologist read).
• Be blind (no light perception), have missing or non-functional eyes.
• Be unable to open their eyes.
• Have a history of unresolved strabismus, diplopia, amblyopia.
• Have a history of unresolved cranial nerve III, IV, or VI palsy.
• Have a history of unresolved macular edema, retinal degeneration, extensive cataract, or ocular globe disruption.
• Have a prior history of unresolved ocular-motor dysfunctions.
• Be intoxicated.
• CONTROLS:
• Provide documented informed consent.
• Be a current cadet/enrolled student age 17-34.
• Have the ability to provide a complete ophthalmologic, medical, and neurologic history as well as report current medications.
• Have presented, within the prior six months, for any complaint related to an injury involving either a direct force to the head or a blow to the body that has the potential to transmit a rapid acceleration/deceleration of the head, with or without loss of consciousness, with or without external signs of head injury.
• Have penetrating trauma or known skull fracture or intracranial injury.

Sponsors & Collaborators

• Oculogica, Inc.: lead
• Congressionally Directed Medical Research Programs: collaborator

Study Sites (1)

Keller Army Hospital

West Point, New York, 10996, United States

Location

MeSH Terms

Conditions

Brain Concussion; Brain Injuries, Traumatic; Disease

Condition Hierarchy (Ancestors)

Brain Injuries; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Craniocerebral Trauma; Trauma, Nervous System; Head Injuries, Closed; Wounds and Injuries; Wounds, Nonpenetrating; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Kenneth Cameron, PhD

  Keller Army Community Hospital

  PRINCIPAL INVESTIGATOR

• Christina Master, MD

  Children's Hospital of Philadelphia

  PRINCIPAL INVESTIGATOR

• Sadie Buboltz-Dubs, PhD

  University of Wisconsin - Green Bay

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 30, 2022
• First Posted: September 2, 2022
• Study Start: July 1, 2023
• Primary Completion: August 1, 2025
• Study Completion: September 26, 2025
• Last Updated: July 31, 2025

Record last verified: 2025-03

Locations

US (1)